Have a feature idea you'd love to see implemented?
Let us know!
RYTM Rhythm Pharmaceuticals Inc
Price (delayed)
$59.03
Market cap
$3.63B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.33
Enterprise value
$3.58B
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within
Highlights
RYTM's revenue has soared by 82% YoY and by 11% QoQ
The gross profit has soared by 82% YoY and by 10% from the previous quarter
The debt has surged by 180% year-on-year but it has declined by 2.1% since the previous quarter
Rhythm Pharmaceuticals's equity has plunged by 94% YoY and by 71% from the previous quarter
The quick ratio has declined by 48% year-on-year and by 47% since the previous quarter
Key stats
What are the main financial stats of RYTM
Market
Valuations
Earnings
Shares outstanding
61.46M
Market cap
$3.63B
Enterprise value
$3.58B
Price to earnings (P/E)
N/A
Price to book (P/B)
321.78
Price to sales (P/S)
32.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.85
Revenue
$112.53M
EBIT
-$239.13M
EBITDA
-$237.53M
Free cash flow
-$124.42M
Per share
Balance sheet
Liquidity
EPS
-$4.33
Free cash flow per share
-$2.03
Book value per share
$0.18
Revenue per share
$1.84
TBVPS
$5.83
Total assets
$363.57M
Total liabilities
$210.88M
Debt
$4.03M
Equity
$11.22M
Working capital
$242.74M
Debt to equity
0.36
Current ratio
3.49
Quick ratio
3.26
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-211.1%
Gross margin
88.6%
Net margin
-230.1%
Operating margin
-236%
Return on assets
-78.3%
Return on equity
-371.1%
Return on invested capital
-130.2%
Return on capital employed
-89.9%
Return on sales
-212.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RYTM stock price
How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
-0.56%
1 week
-1.24%
1 month
17.61%
1 year
76.68%
YTD
28.41%
QTD
12.67%
Financial performance
How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$112.53M
Gross profit
$99.72M
Operating income
-$265.52M
Net income
-$258.91M
Gross margin
88.6%
Net margin
-230.1%
RYTM's revenue has soared by 82% YoY and by 11% QoQ
The gross profit has soared by 82% YoY and by 10% from the previous quarter
Rhythm Pharmaceuticals's operating income has decreased by 43% YoY
RYTM's net income is down by 40% year-on-year
Growth
What is Rhythm Pharmaceuticals's growth rate over time
Valuation
What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
321.78
P/S
32.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.85
The EPS has contracted by 34% YoY
Rhythm Pharmaceuticals's equity has plunged by 94% YoY and by 71% from the previous quarter
RYTM's revenue has soared by 82% YoY and by 11% QoQ
RYTM's price to sales (P/S) is 11% higher than its last 4 quarters average of 28.9
Efficiency
How efficient is Rhythm Pharmaceuticals business performance
The ROE has plunged by 67% from the previous quarter
The ROA has contracted by 47% YoY
Rhythm Pharmaceuticals's return on invested capital has decreased by 45% YoY
The ROS has grown by 24% YoY and by 10% from the previous quarter
Dividends
What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RYTM.
Financial health
How did Rhythm Pharmaceuticals financials performed over time
The total assets is 72% more than the total liabilities
The quick ratio has declined by 48% year-on-year and by 47% since the previous quarter
Rhythm Pharmaceuticals's current ratio has decreased by 47% YoY and by 47% from the previous quarter
The debt is 64% smaller than the equity
The debt has surged by 180% year-on-year but it has declined by 2.1% since the previous quarter
Rhythm Pharmaceuticals's equity has plunged by 94% YoY and by 71% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.